Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, Tan HK, Kumar R, Irani FG, Ho ZZ, Zhang Q, Guccione E, Wai LE, Koh S, Hwang W, Chow WC, Bertoletti A. Tan AT, et al. Among authors: wai le. Gastroenterology. 2019 May;156(6):1862-1876.e9. doi: 10.1053/j.gastro.2019.01.251. Epub 2019 Jan 31. Gastroenterology. 2019. PMID: 30711630 Free article.
Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease.
Tan-Garcia A, Wai LE, Zheng D, Ceccarello E, Jo J, Banu N, Khakpoor A, Chia A, Tham CYL, Tan AT, Hong M, Keng CT, Rivino L, Tan KC, Lee KH, Lim SG, Newell EW, Pavelka N, Chen J, Ginhoux F, Chen Q, Bertoletti A, Dutertre CA. Tan-Garcia A, et al. Among authors: wai le. J Hepatol. 2017 Sep;67(3):490-500. doi: 10.1016/j.jhep.2017.04.023. Epub 2017 May 5. J Hepatol. 2017. PMID: 28483682
Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy.
Tan-Garcia A, Lai F, Sheng Yeong JP, Irac SE, Ng PY, Msallam R, Tatt Lim JC, Wai LE, Tham CYL, Choo SP, Lim T, Young DY, D'Ambrosio R, Degasperi E, Perbellini R, Newell E, Le Bert N, Ginhoux F, Bertoletti A, Chen Q, Dutertre CA. Tan-Garcia A, et al. Among authors: wai le. JHEP Rep. 2019 Dec 6;2(1):100062. doi: 10.1016/j.jhepr.2019.11.006. eCollection 2020 Feb. JHEP Rep. 2019. PMID: 32039403 Free PMC article.
Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.
Tan AT, Meng F, Jin J, Zhang JY, Wang SY, Shi L, Shi M, Li Y, Xie Y, Liu LM, Zhou CB, Chua A, Ho ZZ, Luan J, Zhao J, Li J, Wai LE, Koh S, Wang T, Bertoletti A, Wang FS. Tan AT, et al. Among authors: wai le. Hepatol Commun. 2022 Apr;6(4):841-854. doi: 10.1002/hep4.1857. Epub 2021 Dec 21. Hepatol Commun. 2022. PMID: 34935312 Free PMC article.
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Yang F, Zheng X, Koh S, Lu J, Cheng J, Li P, Du C, Chen Y, Chen X, Yang L, Chen W, Wong RW, Wai LE, Wang T, Zhang Q, Chen W. Yang F, et al. Among authors: wai le. Hepatol Int. 2023 Aug;17(4):850-859. doi: 10.1007/s12072-023-10524-x. Epub 2023 Apr 17. Hepatol Int. 2023. PMID: 37067675 Clinical Trial.
Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy.
Chen Q, Chia A, Hang SK, Lim A, Koh WK, Peng Y, Gao F, Chen J, Ho Z, Wai LE, Kunasegaran K, Tan AT, Le Bert N, Loh CY, Goh YS, Renia L, Dong T, Vathsala A, Bertoletti A. Chen Q, et al. Among authors: wai le. Cell Mol Immunol. 2023 Nov;20(11):1300-1312. doi: 10.1038/s41423-023-01080-3. Epub 2023 Sep 5. Cell Mol Immunol. 2023. PMID: 37666955 Free PMC article.
14 results